Illumina, Inc. Stock

Equities

ILMN

US4523271090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2024-06-24 EDT 5-day change 1st Jan Change
110.2 USD +1.54% Intraday chart for Illumina, Inc. +1.07% -20.83%
Sales 2024 * 4.52B 6.17B Sales 2025 * 4.89B 6.68B Capitalization 17.29B 23.62B
Net income 2024 * -294M -402M Net income 2025 * 313M 427M EV / Sales 2024 * 3.85 x
Net Debt 2024 * 128M 175M Net cash position 2025 * 653M 892M EV / Sales 2025 * 3.4 x
P/E ratio 2024 *
-68.7 x
P/E ratio 2025 *
57.3 x
Employees 10,615
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.29%
1 week+1.07%
Current month+5.72%
1 month+3.53%
3 months-17.77%
6 months-21.62%
Current year-20.83%
More quotes
1 week
106.09
Extreme 106.09
110.65
1 month
100.09
Extreme 100.085
119.00
Current year
100.09
Extreme 100.085
148.19
1 year
89.00
Extreme 89
201.17
3 years
89.00
Extreme 89
526.00
5 years
89.00
Extreme 89
555.77
10 years
89.00
Extreme 89
555.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 23-09-24
Chief Tech/Sci/R&D Officer - 97-12-31
Chief Tech/Sci/R&D Officer 54 22-03-13
Members of the board TitleAgeSince
Director/Board Member 58 12-11-28
Chairman 60 23-06-01
Director/Board Member 64 17-01-26
More insiders
Date Price Change Volume
24-06-24 110.2 +1.54% 3 136 054
24-06-21 108.6 +0.30% 35,653,154
24-06-20 108.2 +0.14% 2,780,422
24-06-18 108.1 -0.89% 2,613,371
24-06-17 109.1 +0.38% 2,562,588

Delayed Quote Nasdaq, June 24, 2024 at 04:00 pm

More quotes
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
108.6 USD
Average target price
150.8 USD
Spread / Average Target
+38.92%
Consensus